2025-521095-66-00RecruitingPhase 1
A study in healthy men to find out how different doses of BI 3009947 are tolerated and how different formulations or food influence how BI 3009947 is taken up into the blood
Boehringer Ingelheim International GmbH1 site in 1 country68 target enrollmentStarted: September 19, 2025Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 68
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study in healthy men to test how well different doses of BI 3776528 are tolerated2024-515222-92-00Boehringer Ingelheim International GmbH118
Completed
Phase 1
A study in healthy men to test how well different doses of BI 3731579 are tolerated2023-510318-25-00Boehringer Ingelheim International GmbH64
Suspended
Phase 1
A study in healthy men to test how BI 1839100 is taken up and handled by the body2024-510870-26-00Boehringer Ingelheim International GmbH16
Completed
Phase 1
A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood2023-506367-33-00Boehringer Ingelheim International GmbH16
Completed
Phase 1
A study in healthy men to test how well different doses of BI 3802876 are tolerated2023-504538-23-00Boehringer Ingelheim International GmbH63